Atlas Brown Inc. Buys 1,285 Shares of Novo Nordisk A/S (NYSE:NVO)

Atlas Brown Inc. boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 33.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 5,130 shares of the company’s stock after purchasing an additional 1,285 shares during the quarter. Atlas Brown Inc.’s holdings in Novo Nordisk A/S were worth $441,000 as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. Strategic Investment Solutions Inc. IL bought a new stake in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Abound Wealth Management increased its holdings in shares of Novo Nordisk A/S by 257.4% in the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after acquiring an additional 157 shares in the last quarter. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S during the third quarter worth about $28,000. Capital Performance Advisors LLP bought a new position in shares of Novo Nordisk A/S during the 3rd quarter valued at about $42,000. Finally, Carolina Wealth Advisors LLC acquired a new position in shares of Novo Nordisk A/S in the 3rd quarter valued at approximately $48,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Up 0.7 %

Shares of NYSE:NVO traded up $0.57 during trading on Friday, hitting $86.21. 5,773,708 shares of the company were exchanged, compared to its average volume of 7,152,096. Novo Nordisk A/S has a fifty-two week low of $81.50 and a fifty-two week high of $148.15. The stock has a market cap of $386.87 billion, a price-to-earnings ratio of 27.90, a P/E/G ratio of 1.37 and a beta of 0.45. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The firm has a fifty day moving average price of $100.86 and a two-hundred day moving average price of $119.79.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on NVO. StockNews.com lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. BNP Paribas raised shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday. Finally, UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.